Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02178579 · ClinicalTrials.gov registry record
Prospective Observation of Cardiac Safety With Proteasome Inhibition
A clinical trial, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- 95
- Enrollment target
NCT02178579: Completed study, sponsored by Vanderbilt University Medical Center.
NCT02178579 is a clinical trial that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 95 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02178579 has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- 95 participants
- Enrollment target
Study Summary
The purpose of this study is to better define and understand potential cardiac toxicities of proteasome inhibitors and to understand optimal management strategies to treat and prevent cardiovascular events.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2014-11 |
| Est. Completion | 2019-07-15 |
What the finished NCT02178579 record still lists
NCT02178579 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 95 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02178579 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02178579 about?
NCT02178579 is a clinical study titled "Prospective Observation of Cardiac Safety With Proteasome Inhibition". The purpose of this study is to better define and understand potential cardiac toxicities of proteasome inhibitors and to understand optimal management strategies to treat and prevent cardiovascular events.
What is the current status of trial NCT02178579?
This trial is currently completed. The enrollment target is 95 participants. The study started on 2014-11. Estimated completion is 2019-07-15.
Who is sponsoring clinical trial NCT02178579?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03339128 · 95 participants · Phase 2
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
- NCT03509961 · 95 participants · Phase 2
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- NCT03694756 · 95 participants · NA
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
- NCT04206215 · 95 participants · NA
Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia